Allogene Therapeutics, Inc. Logo

Allogene Therapeutics, Inc.

Developing off-the-shelf CAR T-cell therapies for cancer and autoimmune diseases.

ALLO | NDAQ

Overview

Corporate Details

ISIN(s):
US0197701065
LEI:
Country:
United States of America
Address:
210 EAST GRAND AVENUE, 94080 SOUTH SAN FRANCISCO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T-cell (AlloCAR T™) therapies. The company's 'off-the-shelf' product platform utilizes T-cells from healthy donors to create readily available treatments designed to be more accessible, scalable, and reliable than patient-specific autologous therapies. Its clinical pipeline targets hematologic malignancies (blood cancers), solid tumors, and autoimmune diseases. Key investigational programs include cemacabtagene ansegedleucel (cema-cel) for large B-cell lymphoma (LBCL), ALLO-316 for renal cell carcinoma (ccRCC), and ALLO-329 for autoimmune diseases. Allogene leverages multiplex gene-engineering and gene-editing capabilities to develop its product candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Allogene Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Allogene Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Allogene Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
FATE THERAPEUTICS INC Logo
Develops off-the-shelf iPSC cell therapies for cancer and autoimmune diseases.
United States of America FATE
FENNEC PHARMACEUTICALS INC. Logo
Prevents chemotherapy-induced hearing loss in children with its sole product, PEDMARK®.
United States of America FENC
FibroBiologics, Inc. Logo
Clinical-stage biotech developing fibroblast cell therapies for chronic diseases.
United States of America FBLG
FIBROGEN INC Logo
Biopharma developing first-in-class therapies for cancer, anemia, and serious conditions.
United States of America FGEN
Fine Foods & Pharmaceuticals Ntm Logo
Contract development & manufacturing of oral solids for pharma, nutraceutical & cosmetic sectors.
Italy FF
Flora Growth Corp. Logo
A diversified firm in pharma distribution, plant-based wellness, and digital assets.
United States of America FLGC
Foghorn Therapeutics Inc. Logo
Pioneering medicines targeting the chromatin regulatory system to treat genetically defined cancers.
United States of America FHTX
Formycon AG Logo
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
Germany FYB
Fortress Biotech, Inc. Logo
Acquires, develops, and commercializes drugs for oncology, gene therapy, and rare diseases.
United States of America FBIO
FRACTYL HEALTH, INC. Logo
Developing gut-targeted endoscopic and gene therapies for obesity and type 2 diabetes.
United States of America GUTS

Talk to a Data Expert

Have a question? We'll get back to you promptly.